Sustained activation of the Aryl hydrocarbon Receptor transcription factor promotes resistance to BRAF-inhibitors in melanoma
Resistance to BRAF inhibitors limits their clinical benefit in melanoma patients. Here, the authors show that the Aryl hydrocarbon Receptor (AhR) is a key mediator of resistant genes and use resveratrol, an AhR antagonist, to revert resistance in melanoma bearing mice.
Main Authors: | Sébastien Corre, Nina Tardif, Nicolas Mouchet, Héloïse M. Leclair, Lise Boussemart, Arthur Gautron, Laura Bachelot, Anthony Perrot, Anatoly Soshilov, Aljosja Rogiers, Florian Rambow, Erwan Dumontet, Karin Tarte, Alban Bessede, Gilles J. Guillemin, Jean-Christophe Marine, Michael S. Denison, David Gilot, Marie-Dominique Galibert |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2018-11-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-018-06951-2 |
Similar Items
-
Role of Flavonoids in the Prevention of AhR-Dependent Resistance During Treatment with BRAF Inhibitors
by: Héloïse M. Leclair, et al.
Published: (2020-07-01) -
CRISPR screens identify tumor‐promoting genes conferring melanoma cell plasticity and resistance
by: Arthur Gautron, et al.
Published: (2021-05-01) -
p53 requires the stress sensor USF1 to direct appropriate cell fate decision.
by: Amine Bouafia, et al.
Published: (2014-01-01) -
Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy
by: Ali Talebi, et al.
Published: (2018-06-01) -
Inhibiteurs de BRAF dans le traitement du cancer : Contribution à l’étude des mécanismes de résistance et des effets secondaires paradoxaux
by: Boussemart, Lise
Published: (2014)